Over the past month, shares of Dendreon (NASDAQ:DNDN) have risen 25%, amid talk that a buyout was a possibility. For now, that talk remains just talk; but the company has found a buyer for its New Jersey facility -- Novartis (NYSE:NVS) -- which will raise $43M for the company. In this video, Motley Fool health-care analyst David Williamson tells us why the sale was important for Dendreon, how Novartis will be putting its new facility to use, and if the rumor mill's buyout ideas may materialize somewhere down the road.
Brenton Flynn has no positions in the stocks mentioned above. David Williamson has no positions in the stocks mentioned above. The Motley Fool owns shares of Dendreon and Johnson & Johnson. Motley Fool newsletter services recommend Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.